TABLE 2.

Progression‐free survival (PFS): univariate and multivariate analyses in the bendamustine and rituximab (BR) cohort

	Univariate		Multivariate
	HR (95% CI)	P	HR (95% CI)	P
Age > 65 vs ≤ 65 years	1.85 (0.66‐5.24)	0.24
Binet B‐C vs Binet A	2.16 (0.95‐4.92)	0.07
beta 2 microglobulin ≥ 3.5 vs < 3.5 mg/L	1.64 (0.57‐4.70)	0.36
IGHV unmutated vs mutated	2.29 (0.92‐5.69)	0.07
17p‐ and/or TP53 mutated yes vs no	3.14 (1.29‐7.63)	0.01	2.52 (1.00‐6.39)	0.05
Gender female vs male	0.60 (0.31‐1.17)	0.13
ECOG 0 vs 1	1.64 (0.78‐3.46)	0.19
ECOG 0 vs ≥ 2	3.12 (1.25‐7.81)	0.02
Comorbidities 0‐1 vs ≥ 2	2.91 (1.14‐7.45)	0.03
Creatinine clearance ≤ 70 vs > 70 mL/min	1.76 (0.69‐4.54)	0.24